IGCS 2010, 23-26 October, Prague
The use of an intra-uterine device to treat early stage uterine cancer
Dr Lucas Minig – Hospital Universitario Madrid Sanchinarro, Spain
Lucas, recently you published a very nice paper in Annals of Oncology describing the use of an intra-uterine device to prevent cancer of the endometrium. Can you explain a little bit about this, your findings?
Yes, this is a pilot study. We conducted this study at the European Institute of Oncology in Milan since November 1999 to December 2009 and we studied young women, less than forty years old, who had endometrial cancer, early endometrial cancer, well differentiated and a typical endometrial population who wished to get pregnant in the future. We tested the efficacy of an IUD with Mirena, with an IUD with levonorgestrel plus GnRH analogue for treating this disease.
And so these women were given this IUD for a short period of time and you saw that it prevented the development of cancer?
Yes, we used this treatment for one year with the IUD and for six months the analogue. We did a monthly injection of these analogues of GnRH plus the IUD for one year and we tested the efficacy with a biopsy guided by a hysteroscopy at six months and at one year.
But this could be used for any woman, not only women that want to get pregnant.
Yes, we tested this treatment in young women, in only first young women but also there exists now evidence that we can use this treatment for women who have this disease but they have serious contra-indications for surgical treatment which is the standard of care for this specific disease. The surgical treatment means hysterectomy, so that’s why it’s very important for young women.
And could it also be used to prevent cancer in women that have maybe very early stage atypical dysplasia but not yet cancer?
Yes, we observed, in fact, more efficacy in women with a endometrial atypical hyperplasia rather than endometrial cancer. We observed, in fact, 97% of complete response after one year of treatment in those patients with endometrial atypical hyperplasia and a complete response of 60% in those patients with well differentiated endometrial cancer.
So now what is going to happen? Is there going to be a clinical trial?
The next step, in fact we tested only twenty patients with endometrial atypical hyperplasia and fourteen patients with endometrial cancer. So our results were encouraging, we think, in developing an international study in multiple centres around Europe or also around the world for testing the different modalities of conservative treatment of this specific disease in this specific population. Because nowadays in several parts of the world different physicians are using, for example, oral progesterones as a conservative treatment or IUD as us, or also endometrial ablation guided by hysteroscopy of the tumour. So we are now thinking of developing this protocol by using all of these strategies but with the same preparative evaluation and with the same type of follow-up after these different types of treatments.